Pharming Group (PHAR) Competitors $7.68 +0.13 (+1.72%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends PHAR vs. MIRM, SUPN, CNTA, MNKD, GPCR, HRMY, EVO, IRON, GLPG, and XNCRShould you be buying Pharming Group stock or one of its competitors? The main competitors of Pharming Group include Mirum Pharmaceuticals (MIRM), Supernus Pharmaceuticals (SUPN), Centessa Pharmaceuticals (CNTA), MannKind (MNKD), Structure Therapeutics (GPCR), Harmony Biosciences (HRMY), Evotec (EVO), Disc Medicine (IRON), Galapagos (GLPG), and Xencor (XNCR). These companies are all part of the "pharmaceutical preparations" industry. Pharming Group vs. Mirum Pharmaceuticals Supernus Pharmaceuticals Centessa Pharmaceuticals MannKind Structure Therapeutics Harmony Biosciences Evotec Disc Medicine Galapagos Xencor Mirum Pharmaceuticals (NASDAQ:MIRM) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations. Is MIRM or PHAR more profitable? Pharming Group has a net margin of -6.09% compared to Mirum Pharmaceuticals' net margin of -31.69%. Pharming Group's return on equity of -7.65% beat Mirum Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Mirum Pharmaceuticals-31.69% -41.22% -14.81% Pharming Group -6.09%-7.65%-3.82% Does the MarketBeat Community favor MIRM or PHAR? Mirum Pharmaceuticals received 113 more outperform votes than Pharming Group when rated by MarketBeat users. Likewise, 75.58% of users gave Mirum Pharmaceuticals an outperform vote while only 60.71% of users gave Pharming Group an outperform vote. CompanyUnderperformOutperformMirum PharmaceuticalsOutperform Votes13075.58% Underperform Votes4224.42% Pharming GroupOutperform Votes1760.71% Underperform Votes1139.29% Does the media favor MIRM or PHAR? In the previous week, Mirum Pharmaceuticals had 30 more articles in the media than Pharming Group. MarketBeat recorded 31 mentions for Mirum Pharmaceuticals and 1 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.11 beat Mirum Pharmaceuticals' score of 0.64 indicating that Pharming Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 11 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of MIRM or PHAR? 0.0% of Pharming Group shares are held by institutional investors. 22.9% of Mirum Pharmaceuticals shares are held by insiders. Comparatively, 2.1% of Pharming Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has higher valuation & earnings, MIRM or PHAR? Pharming Group has higher revenue and earnings than Mirum Pharmaceuticals. Pharming Group is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMirum Pharmaceuticals$186.37M11.25-$163.41M-$2.02-21.63Pharming Group$245.32M2.12-$10.55M-$0.26-29.54 Which has more volatility & risk, MIRM or PHAR? Mirum Pharmaceuticals has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, Pharming Group has a beta of 0.13, suggesting that its share price is 87% less volatile than the S&P 500. Do analysts rate MIRM or PHAR? Mirum Pharmaceuticals presently has a consensus target price of $57.73, suggesting a potential upside of 32.13%. Pharming Group has a consensus target price of $33.50, suggesting a potential upside of 336.20%. Given Pharming Group's higher possible upside, analysts plainly believe Pharming Group is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.17Pharming Group 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryMirum Pharmaceuticals beats Pharming Group on 10 of the 19 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Pharming Group News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHAR vs. The Competition Export to ExcelMetricPharming GroupPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$520.97M$6.45B$5.03B$8.81BDividend YieldN/A8.11%5.16%4.06%P/E Ratio-29.5410.78135.4117.82Price / Sales1.82243.751,160.9774.56Price / Cash83.9222.1633.5332.53Price / Book2.365.474.674.68Net Income-$10.55M$153.61M$119.07M$226.08M7 Day Performance-2.78%-2.00%-1.83%-1.04%1 Month Performance-13.80%-7.46%-3.60%1.04%1 Year Performance-34.07%31.82%31.66%26.28% Pharming Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHARPharming Group2.1577 of 5 stars$7.68+1.7%$33.50+336.2%-31.4%$511.88M$245.32M-29.54382Positive NewsMIRMMirum Pharmaceuticals4.2959 of 5 stars$43.69+3.8%$57.73+32.1%+36.1%$2.02B$186.37M0.00140Analyst RevisionSUPNSupernus Pharmaceuticals2.3042 of 5 stars$36.12+1.7%$36.00-0.3%+32.3%$1.96B$607.52M33.76580Positive NewsCNTACentessa Pharmaceuticals4.06 of 5 stars$16.74-0.5%$25.83+54.3%+144.7%$1.91B$6.85M0.0072MNKDMannKind3.454 of 5 stars$6.88+0.3%$8.67+26.0%+83.0%$1.89B$198.96M98.29400Insider TradeGPCRStructure Therapeutics2.2818 of 5 stars$32.71-0.2%$86.80+165.4%-38.8%$1.88BN/A-44.20136Analyst RevisionHRMYHarmony Biosciences4.7919 of 5 stars$32.79+1.0%$47.00+43.3%+18.1%$1.85B$582.02M15.54200EVOEvotec1.9292 of 5 stars$5.30+2.9%$5.93+11.9%-49.7%$1.83B$845.74M0.005,061IRONDisc Medicine3.1676 of 5 stars$62.55+5.0%$85.80+37.2%+22.4%$1.77BN/A0.0078Insider TradeAnalyst RevisionGLPGGalapagos1.2816 of 5 stars$25.64-3.9%$30.75+19.9%-31.4%$1.76B$259.40M0.001,123Analyst DowngradeShort Interest ↓News CoverageGap DownXNCRXencor3.5491 of 5 stars$23.72+0.4%$35.75+50.7%+19.3%$1.65B$168.34M-7.41280 Related Companies and Tools Related Companies MIRM Competitors SUPN Competitors CNTA Competitors MNKD Competitors GPCR Competitors HRMY Competitors EVO Competitors IRON Competitors GLPG Competitors XNCR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PHAR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharming Group Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharming Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHAR Stock Alerts